Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca ( (GB:AZN) ) has issued an update.
AstraZeneca has reported that deferred share awards granted in March 2023 under its AstraZeneca Deferred Bonus Plan have vested for senior executives, following the completion of a three-year holding period tied to 2022 performance. Chief executive Pascal Soriot acquired 14,967 ordinary shares and chief financial officer Aradhana Sarin received 4,863 shares, after dividend reinvestment and tax-related withholdings, at a fair market value of 14,932 pence per share for tax purposes.
The transactions, conducted for nil consideration and outside a trading venue, increase the executives’ beneficial interests in the company and reinforce AstraZeneca’s pay-for-performance alignment between management and shareholders. The disclosure, made in line with EU Market Abuse Regulation requirements as incorporated into U.K. law, provides investors with additional transparency on insider equity holdings at the FTSE-listed drugmaker.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca PLC (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company headquartered in Cambridge, U.K., focused on discovering, developing and commercialising prescription medicines. Its core therapeutic areas include Oncology, Rare Diseases and BioPharmaceuticals, spanning Cardiovascular, Renal & Metabolism and Respiratory & Immunology, with products sold in more than 125 countries.
Average Trading Volume: 2,695,814
Technical Sentiment Signal: Buy
Current Market Cap: £229.1B
For detailed information about AZN stock, go to TipRanks’ Stock Analysis page.